These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 8522474)
21. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis]. Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria. Piddock LJ; Panchal S; Norte V J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493 [TBL] [Abstract][Full Text] [Related]
23. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds. Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615 [TBL] [Abstract][Full Text] [Related]
24. Comparative activities of eight quinolones against members of the Bacteroides fragilis group. Borobio MV; Conejo M; Ramirez E; Suarez AI; Perea EJ Antimicrob Agents Chemother; 1994 Jun; 38(6):1442-5. PubMed ID: 8092852 [TBL] [Abstract][Full Text] [Related]
25. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094 [TBL] [Abstract][Full Text] [Related]
26. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin. Carlyn CJ; Doyle LJ; Knapp CC; Ludwig MD; Washington JA Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114 [TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activities of new quinolones against coryneform bacteria. Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of action of quinolones against staphylococci and relationship with their in vitro bactericidal activity. Ramón MS; Cantón E; Pemán J; Pastor A; Martínez JP Chemotherapy; 1999; 45(3):175-82. PubMed ID: 10224339 [TBL] [Abstract][Full Text] [Related]
29. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents. Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440 [TBL] [Abstract][Full Text] [Related]
30. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Crokaert F; Aoun M; Duchateau V; Grenier P; Vandermies A; Klastersky J Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):696-8. PubMed ID: 8894585 [No Abstract] [Full Text] [Related]
31. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237 [TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202 [TBL] [Abstract][Full Text] [Related]
33. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone. Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464 [TBL] [Abstract][Full Text] [Related]